HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma

Laboratory Investigation

Volumn 91, Issue 1, 2011, Pages 124-137

  Bu, Rong ^a   Uddin, Shahab ^a   Bavi, Prashant ^a   Hussain, Azhar R ^a   Al Dayel, Fouad ^a   Ghourab, Samir ^a   Ahmed, Maqbool ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

AKT; apoptosis; epithelial ovarian carcinoma; hepatocyte growth factor; hepatocyte growth factor c Met pathway; tissue microarray

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CASPASE 3; CASPASE 9; CISPLATIN; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL VIABILITY; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL OVARIAN CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; SAUDI ARABIA; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-X PROTEIN; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; ENZYME ACTIVATION; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SULFONES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650781733     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.136     Document Type: Article

References (54)

1. Philchenkov A. Caspases: potential targets for regulating cell death. J Cell Mol Med 2004;8:432-444.
2. Deveraux QL, Takahashi R, Salvesen GS, et al. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997;388:300-304.
3. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001;6:253-261.
4. Lacasse EC, Baird S, Korneluk RG, et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998;17:3247-3259.
5. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-1803.
6. Yang L, Cao ZH, Yan H, et al. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003;63:6815-6824.
7. Mansouri A, Zhang QX, Ridgway LD, et al. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 2003;13: 399-404.
8. Sapi E, Alvero AB, Chen W, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004;14:567-578.
9. Sasaki H, Sheng YL, Kotsuji F, et al. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000;60:5659-5666.
10. La Casse EC, Cherton-Horvat GG, Hewitt KE, et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 2006;12:5231-5241.
11. Lacasse EC, Kandimalla ER, Winocour P, et al. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/GEM640. Ann NY Acad Sci 2005;1058:215-234.
12. Shaw TJ, Lacasse EC, Durkin JP, et al. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer 2008;122:1430-1434.
13. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22:309-325.
14. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-1679.
15. Koon EC, Ma PC, Salgia R, et al. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 2008;18:976-984.
16. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/ Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98:247-252.
17. Shinomiya N, Gao CF, Xie Q, et al. RNA interference reveals that ligand-independent MET activity is required for tumor cell signaling and survival. Cancer Res 2004;64:7962-7970.
18. Uddin S, Hussain AR, Al-Hussein KA, et al. Inhibition of phosphatidylinositol 3V-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005;11:3102-3108.
19. Takeuchi H, Kim J, Fujimoto A, et al. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin Cancer Res 2005;11:7621-7628.
20. Russel P. Blaustein's Pathology of the Female Genital Tract. Springer-Verlag: New York, 1995.
21. Bavi P, Abubaker J, Hussain A, et al. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008;39:885-894.
22. Uddin S, Bavi P, Hussain AR, et al. Leptin receptor expression in middle Eastern colorectal cancer and it's potential clinical implication. Carcinogenesis 2009;30:1832-1840.
23. Kang JY, Dolled-Filhart M, Ocal IT, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003;63:1101-1105.
24. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003;97:1841-1848.
25. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-682.
26. Uddin S, Bu R, Ahmed M, et al. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer 2009;8:74-85.
27. Uddin S, Ahmed M, Hussain A, et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer 2010;126:382-394.
28. 0-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006;11:245-254.
29. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidum iodide staining. J Cell Biol 1975;66:188-193.
30. 0-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-4186.
31. Uddin S, Ah-Kang J, Ulaszek J, et al. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci USA 2004;101:147-152.
32. Hussain AR, Al-Jomah NA, Siraj AK, et al. Sanguinarine- dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007;8:3888-3897.
33. Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005;47:7022-7030.
34. Bazzaro M, Lee MK, Zoso A, et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006;66:3754-3763.
35. Sawada K, Radjabi AR, Shinomiya N, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-1679.
36. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;1:1-26.
37. Tjin EP, Groen RW, Vogelzang I, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006;107:760-768.
38. Daugaard G. Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 1990;37:1-12.
39. Verstappen C, Heimans J, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003;63:1549-1563.
40. Kuhar M, Imran S, Singh N. Curcumin and quercetin combined with cisplatin to induce apoptosis in human laryngeal carcinoma Hep-2 cells through the mitochondrial pathway. J Cancer Mol 2007;3:121-128.
41. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 2000; 19:5582-5589.
42. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998;58:1808-1812.
43. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001;95:92-95.
44. Cao C, Mu Y, Hallahan DE, et al. XIAP and surviving as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004;23:7047-7052.
45. Di Renzo MF, Olivero M, Katsaros D, et al. Overexpression of the MET/ HGF receptor in ovarian cancer. Int J Cancer 1994;58:658-662.
46. Olivero M, Ruggiero T, Saviozzi S, et al. Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Mol Cancer Ther 2006;5:1126-1135.
47. Coltella N, Rasola A, Nano E, et al. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer 2006;118: 2981-2990.
48. Rasola A, Anguissola S, Ferrero N, et al. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res 2004;64:1744-1750.
49. Mildner M, Eckhart L, Lengauer B, et al. Hepatocyte growth factor/ scatter factor inhibits UVB-induced apoptosis of human keratinocytes but not of keratinocyte-derived cell lines via the phosphatidylinositol 3-kinase/AKT pathway. J Biol Chem 2002;277:14146-14152.
50. Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/ scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3-kinase. Oncogene 2000;19:2212-2223.
51. Fan S, Wang JA, Yuan RQ, et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 1998;17:131-141.
52. Okano J, Shiota G, Matsumoto K, et al. Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/Akt signaling pathway. Biochem Biophys Res Commun 2003;309: 298-304.
53. Sonoda Y, Matsumoto Y, Funakoshi M, et al. Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 2000;275: 16309-16315.
54. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004;279:5405-5412.